Creon ® — Net Sales
Viatris Creon ® — Net Sales decreased by 1.5% to $97.40M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 18.2%, from $82.40M to $97.40M. Over 4 years (FY 2021 to FY 2025), Creon ® — Net Sales shows an upward trend with a 4.2% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates growing market demand, successful commercial execution, or effective pricing strategies for the product, while a decrease may signal increased competition, patent expirations, or shifts in clinical prescribing patterns.
Detailed definition
This metric represents the total revenue generated from the sale of a specific branded pharmaceutical product after acco...
Peer comparison
Comparable to branded pharmaceutical product revenue lines reported by peers in the specialty or digestive health segments, often evaluated against broader therapeutic class growth rates.
vtrs_segment_creon_net_salesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $80.70M | $81.10M | $78.10M | $74.70M | $75.40M | $76.40M | $77.50M | $72.70M | $74.10M | $77.50M | $80.60M | $75.00M | $78.20M | $84.60M | $90.40M | $82.40M | $91.40M | $93.10M | $98.90M | $97.40M |
| QoQ Change | — | +0.5% | -3.7% | -4.4% | +0.9% | +1.3% | +1.4% | -6.2% | +1.9% | +4.6% | +4.0% | -6.9% | +4.3% | +8.2% | +6.9% | -8.8% | +10.9% | +1.9% | +6.2% | -1.5% |
| YoY Change | — | — | — | — | -6.6% | -5.8% | -0.8% | -2.7% | -1.7% | +1.4% | +4.0% | +3.2% | +5.5% | +9.2% | +12.2% | +9.9% | +16.9% | +10.0% | +9.4% | +18.2% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Viatris's creon ® — net sales?
- Viatris (VTRS) reported creon ® — net sales of $97.40M in Q1 2026.
- How has Viatris's creon ® — net sales changed year-over-year?
- Viatris's creon ® — net sales increased by 18.2% year-over-year, from $82.40M to $97.40M.
- What is the long-term trend for Viatris's creon ® — net sales?
- Over 4 years (2021 to 2025), Viatris's creon ® — net sales has grown at a 4.2% compound annual growth rate (CAGR), from $309.80M to $365.80M.
- What does creon ® — net sales mean?
- The total revenue earned from sales of the Creon branded medication.